To: All XDEA Waivered Prescribers

From: Division of Medical Services

Effective Jan. 1, 2020, Arkansas Medicaid is putting measures in place to comply with Act 964 of 2019 regarding Medication Assisted Treatment (MAT). Pursuant to this act, Medicaid will remove the prior authorization requirement on the following drugs used to treat opioid use disorder:

- Suboxone film (buprenorphine/naloxone sublingual film)
- Buprenorphine sublingual tablets

In order to receive MAT, a client must have a valid prescription, and the treatment must follow the guidelines issued by the Substance Abuse and Mental Health Services Administration (SAMHSA) that are current as of the date of treatment. Medical necessity reviews will be conducted in accordance with SAMSHA guidelines. For more information on these guidelines, please visit [SAMSHA’s website](https://www.samhsa.gov).

Medicaid will conduct webinars and work with third-party oversight agencies to increase compliance and educate providers on how to access MAT and comply with SAMSHA guidelines.

If you have additional questions or need assistance, please contact your AFMC Provider Relations outreach specialist.

Sincerely,
AFMC Provider Relations